Asia Pacific Viral Vector And Plasmid DNA Manufacturing Market Size | Companies
The Asia Pacific viral vector and plasmid DNA manufacturing market size was exhibited at USD 1.90 billion in 2023 and is projected to hit around USD 13.88 billion by 2033, growing at a CAGR of 22.0% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 2.32 Billion |
| Market Size by 2033 | USD 13.88 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 22.0% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Vector Type, Workflow, Application, End-use, Disease |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | Asia Pacific |
| Key Companies Profiled | FUJIFILM Holdings Corporation; Wuxi Biologics; Takara Bio Inc.; Astellas Pharma, Inc. (Audentes Therapeutics); Lonza; Charles River Laboratories (Cobra Biologics); Virovek Incorporation; BioMarin |
The growth is attributed to the growing incidence of target conditions and diseases, as well as the effectiveness of pDNA in delivering gene therapy. Furthermore, funding for the advancement of gene therapy as well as ongoing research on genes as well as cell therapies dependent on viral vectors are factors contributing to this growth.
Asia Pacific accounted for the share of 19.3% of the global viral vector and plasmid DNA manufacturing market in 2023. An increasing number of clinical trials with promising results, a growing incidence of chronic diseases, and growing efforts to advance gene therapy are the main drivers of the market. The region holds a significant elderly population, with Thailand, Japan, and China among the key countries in this context. The rapidly aging population in these countries is expected to boost the demand for viral vectors and plasmid DNA manufacturing in the region.
The local presence of companies and research institutes, such as Sirion-Biotech GmbH, which are specifically engaged in vector research and manufacturing, is driving the country’s market. For instance, in March 2022, GenScript ProBio and the National Cancer Center for Japan entered into a research collaboration to develop a lentiviral and plasmid vector for CMC. This collaboration was anticipated to boost the R&D of novel viral vectors and pDNA, thereby driving the market.
The adeno-associated virus (AAV) segment led the market with the largest revenue share of 20.1% in 2023. Increase adoption of AAV as it offers maximum precision in delivering the gene and is increasingly being used for various research applications in gene therapy. Furthermore, the use of AAV-based vectors is increasing in neuroscience research studies as a preclinical tool. This research space uses AAV-based vectors for brain connectivity mapping and interrogating neurocircuit & cellular functions.
The lentivirus segment is projected to grow at the fastest CAGR of 22.0% during the forecast period. Lentiviral vectors have witnessed significant success in reprogramming induced pluripotent stem cells. Lentiviral vectors have been used with a Cre-Lox-based reversible system, leading to the opening of new areas for research. This has created opportunities for therapeutic research for iPSC technology.
The downstream processing segment dominated the market with a revenue share of 53.6% in 2023. The downstream processes involve several purification methods that include multiple steps. The processes are usually divided into three stages: capture, intermediate purification, and polishing.
The upstream processing segment is expected to grow at a CAGR of 21.0% over the forecast period. The initial stage of processing, known as upstream processing, includes introducing cells to the virus, cultivating these cells, and then isolating the virus from them. The growing innovation in product development, such as the ambr 15 microbioreactor system for high-throughput upstream process development, is anticipated to advance this particular field.
The vaccinology segment accounted for the largest revenue share of 22.0% in 2023. The increasing need for vaccines to treat infectious diseases is estimated to drive market growth. Various viral vectors are currently under investigation due to their associated benefits, showing promise for expediting the development of viral vector-based vaccines.
The cell therapy segment is expected to grow at a CAGR of 24.2% over the forecast period. Cell therapy-based medicines are increasingly being adopted owing to the advent of next-generation transfer vectors. These vectors are proven to be safe and efficacious. Patient samples are generally expanded, extracted, and further transduced by using gene therapy vectors.
The research institutes segment dominated the market with a revenue share of 57.7% in 2023. The segment growth is attributed to the increase in the demand for viral vectors and the increasing involvement of scientific communities in gene and cell therapy research. Research activities carried out for improvement in vector production by research entities are driving the segment growth.
The pharmaceutical and biotechnology companies segment is expected to grow at a CAGR of 22.2% over the forecast period. With increasing investments in the field of cell and gene therapy, several biopharmaceutical companies are shifting their focus toward these advanced therapies. This has resulted in more research studies being conducted by companies to evaluate the potential of gene and cell therapies. Emerging biotechnology and pharmaceutical companies are actively engaged in the development of advanced therapies for several life-threatening diseases.
The cancer segment held the largest revenue share of 38.18% in 2023. The segment's growth is expected to be driven by an increasing number of cancer cases and a high volume of plasmid DNA and viral vectors used in developing gene therapies. Additionally, the adoption of a Western lifestyle, poor diet, and lack of physical activity are contributing to the rise in cancer cases.
The genetic disorders segment is expected to grow at a CAGR of 22.0% during the forecast period. Gene therapy has been developed to treat rare genetic disorders such as hemophilia, Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID), and Lipoprotein Lipase Deficiency (LPLD). These conditions are caused by genetic abnormalities or missing genes that affect certain traits. Most genetic disorders are present from birth, but some can develop due to random mutations. Common genetic diseases include sickle cell anemia and hemophilia, which involve blood clot formation and abnormal hemoglobin production, impacting the blood's ability to carry oxygen.
China Viral Vector And Plasmid DNA Manufacturing Market Trends
TheChina viral vector and plasmid DNA manufacturing market accounted for a revenue share of 19.6% in 2023 owing to advancements in the regulatory framework for cell-based research activities in the country. Furthermore, several biopharmaceutical companies are shifting their focus toward these advanced therapies with increasing investment in the field of cell & gene therapy. For instance, in April 2022, VectorBuilder announced an investment of USD 500 million to build a new cell research and gene therapy research & manufacturing facility in Guangzhou, China. This production facility has the ability to produce viral and non-viral forms of vectors, including AAV, plasmids, cell lines, lentivirus, and mRNA. This investment is expected to drive viral vectors and the plasmid DNA manufacturing market in China.
Japan Viral Vector And Plasmid DNA Manufacturing Market Trends
The Japan viral vector and plasmid DNA manufacturing market is anticipated to grow at a CAGR of 20.6% over the forecast period, as it has one of the most developed pharmaceutical and biotechnology sectors in the region. Moreover, the high prevalence of chronic diseases and rare genetic disorders has led to an increase in R&D activities for the development of novel therapies and vaccines, creating a high demand for pDNA manufacturing solutions for research purposes.
In June 2022, Charles River Laboratories expanded its cell and gene therapy products portfolio to include CDMO services covering viral vectors, cellular therapy, and plasmid DNA production.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Asia Pacific viral vector and plasmid DNA manufacturing market
Vector Type
Workflow
Application
End-use
Disease
Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vector type
1.2.2. Workflow
1.2.3. Application
1.2.4. End-use
1.2.5. Disease
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
3.2.1.2. Technological Advancements in Manufacturing Vectors
3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
3.2.2. Market restraint analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis
4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
4.2. Adeno-associated virus (AAV)
4.2.1. Market estimates and forecasts 2021 to 2033
4.3. Lentivirus
4.3.1. Market estimates and forecasts 2021 to 2033
4.4. Adenovirus
4.4.1. Market estimates and forecasts 2021 to 2033
4.5. Retrovirus
4.5.1. Market estimates and forecasts 2021 to 2033
4.6. Plasmids
4.6.1. Market estimates and forecasts 2021 to 2033
4.7. Others
4.7.1. Market estimates and forecasts 2021 to 2033
Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis
5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
5.2. Upstream Manufacturing
5.2.1. Market estimates and forecasts 2021 to 2033
5.2.2. Vector Amplification & Expansion
5.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.3. Vector Recovery/Harvesting
5.2.3.1. Market estimates and forecasts 2021 to 2033
5.3. Downstream Manufacturing
5.3.1. Market estimates and forecasts 2021 to 2033
5.3.2. Purification
5.3.2.1. Market estimates and forecasts 2021 to 2033
5.3.3. Fill Finish diagnostic instruments
5.3.3.1. Market estimates and forecasts 2021 to 2033
Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis
6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
6.2. Gene Therapy
6.2.1. Market estimates and forecasts 2021 to 2033
6.3. Cell Therapy
6.3.1. Market estimates and forecasts 2021 to 2033
6.4. Vaccinology
6.4.1. Market estimates and forecasts 2021 to 2033
6.5. Research Applications
6.5.1. Market estimates and forecasts 2021 to 2033
Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis
7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
7.2. Pharmaceutical and Biopharmaceutical Companies
7.2.1. Market estimates and forecasts 2021 to 2033
7.3. Research Institutes
7.3.1. Market estimates and forecasts 2021 to 2033
Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis
8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
8.2. Cancer
8.2.1. Market estimates and forecasts 2021 to 2033
8.3. Genetic Disorders
8.3.1. Market estimates and forecasts 2021 to 2033
8.4. Infectious Diseases
8.4.1. Market estimates and forecasts 2021 to 2033
8.5. Other
8.5.1. Market estimates and forecasts 2021 to 2033
Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2024 & 2033
9.2. North America
9.2.1. North America market estimates and forecasts 2021 to 2033
9.2.2. U.S.
9.2.2.1. Key country dynamics
9.2.2.2. Regulatory framework
9.2.2.3. Competitive scenario
9.2.2.4. U.S. market estimates and forecasts 2021 to 2033
9.2.2.5. Target disease prevalence
9.2.3. Canada
9.2.3.1. Key country dynamics
9.2.3.2. Regulatory framework
9.2.3.3. Competitive scenario
9.2.3.4. Canada market estimates and forecasts 2021 to 2033
9.2.3.5. Target disease prevalence
9.3. Europe
9.3.1. Europe market estimates and forecasts 2021 to 2033
9.3.2. UK
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. UK market estimates and forecasts 2021 to 2033
9.3.2.5. Target disease prevalence
9.3.3. Germany
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Germany market estimates and forecasts 2021 to 2033
9.3.3.5. Target disease prevalence
9.3.4. France
9.3.4.1. Key country dynamics
9.3.4.2. Regulatory framework
9.3.4.3. Competitive scenario
9.3.4.4. France market estimates and forecasts 2021 to 2033
9.3.4.5. Target disease prevalence
9.3.5. Italy
9.3.5.1. Key country dynamics
9.3.5.2. Regulatory framework
9.3.5.3. Competitive scenario
9.3.5.4. Italy market estimates and forecasts 2021 to 2033
9.3.5.5. Target disease prevalence
9.3.6. Spain
9.3.6.1. Key country dynamics
9.3.6.2. Regulatory framework
9.3.6.3. Competitive scenario
9.3.6.4. Spain market estimates and forecasts 2021 to 2033
9.3.6.5. Target disease prevalence
9.3.7. Norway
9.3.7.1. Key country dynamics
9.3.7.2. Regulatory framework
9.3.7.3. Competitive scenario
9.3.7.4. Norway market estimates and forecasts 2021 to 2033
9.3.7.5. Target disease prevalence
9.3.8. Sweden
9.3.8.1. Key country dynamics
9.3.8.2. Regulatory framework
9.3.8.3. Competitive scenario
9.3.8.4. Sweden market estimates and forecasts 2021 to 2033
9.3.8.5. Target disease prevalence
9.3.9. Denmark
9.3.9.1. Key country dynamics
9.3.9.2. Regulatory framework
9.3.9.3. Competitive scenario
9.3.9.4. Denmark market estimates and forecasts 2021 to 2033
9.3.9.5. Target disease prevalence
9.4. Asia Pacific
9.4.1. Asia Pacific market estimates and forecasts 2021 to 2033
9.4.2. Japan
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Japan market estimates and forecasts 2021 to 2033
9.4.2.5. Target disease prevalence
9.4.3. China
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. China market estimates and forecasts 2021 to 2033
9.4.3.5. Target disease prevalence
9.4.4. India
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. India market estimates and forecasts 2021 to 2033
9.4.4.5. Target disease prevalence
9.4.5. Australia
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Australia market estimates and forecasts 2021 to 2033
9.4.5.5. Target disease prevalence
9.4.6. South Korea
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. South Korea market estimates and forecasts 2021 to 2033
9.4.6.5. Target disease prevalence
9.4.7. Thailand
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Thailand market estimates and forecasts 2021 to 2033
9.4.7.5. Target disease prevalence
9.5. Latin America
9.5.1. Latin America market estimates and forecasts 2021 to 2033
9.5.2. Brazil
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. Brazil market estimates and forecasts 2021 to 2033
9.5.2.5. Target disease prevalence
9.5.3. Mexico
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. Mexico market estimates and forecasts 2021 to 2033
9.5.3.5. Target disease prevalence
9.5.4. Argentina
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Argentina market estimates and forecasts 2021 to 2033
9.5.4.5. Target disease prevalence
9.6. MEA
9.6.1. MEA market estimates and forecasts 2021 to 2033
9.6.2. South Africa
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. South Africa market estimates and forecasts 2021 to 2033
9.6.2.5. Target disease prevalence
9.6.3. Saudi Arabia
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework
9.6.3.3. Competitive scenario
9.6.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033
9.6.3.5. Target disease prevalence
9.6.4. UAE
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework
9.6.4.3. Competitive scenario
9.6.4.4. UAE market estimates and forecasts 2021 to 2033
9.6.4.5. Target disease prevalence
9.6.5. Kuwait
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework
9.6.5.3. Competitive scenario
9.6.5.4. Kuwait market estimates and forecasts 2021 to 2033
9.6.5.5. Target disease prevalence
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2024
10.4. Company Profiles/Listing
10.4.1. Merck KGaA
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Lonza
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. FUJIFILM Diosynth Biotechnologies
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Thermo Fisher Scientific
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Cobra Biologics
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Catalent Inc.
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Wuxi Biologics
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Takara Bio Inc.
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Waisman Biomanufacturing
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Genezen laboratories
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
10.4.11. Batavia Biosciences
10.4.11.1. Company overview
10.4.11.2. Financial performance
10.4.11.3. Product benchmarking
10.4.11.4. Strategic initiatives
10.4.12. Miltenyi Biotec GmbH
10.4.12.1. Company overview
10.4.12.2. Financial performance
10.4.12.3. Product benchmarking
10.4.12.4. Strategic initiatives
10.4.13. SIRION Biotech GmbH
10.4.13.1. Company overview
10.4.13.2. Financial performance
10.4.13.3. Product benchmarking
10.4.13.4. Strategic initiatives
10.4.14. Virovek Incorporation
10.4.14.1. Company overview
10.4.14.2. Financial performance
10.4.14.3. Product benchmarking
10.4.14.4. Strategic initiatives
10.4.15. BioNTech IMFS GmbH
10.4.15.1. Company overview
10.4.15.2. Financial performance
10.4.15.3. Product benchmarking
10.4.15.4. Strategic initiatives
10.4.16. Audentes Therapeutics
10.4.16.1. Company overview
10.4.16.2. Financial performance
10.4.16.3. Product benchmarking
10.4.16.4. Strategic initiatives
10.4.17. BioMarin Pharmaceutical
10.4.17.1. Company overview
10.4.17.2. Financial performance
10.4.17.3. Product benchmarking
10.4.17.4. Strategic initiatives
10.4.18. RegenxBio, Inc.
10.4.18.1. Company overview
10.4.18.2. Financial performance
10.4.18.3. Product benchmarking
10.4.18.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers